A locked transcriptomic panel improves prediction of biochemical recurrence after radical prostatectomy

BACKGROUND After radical prostatectomy, clinical variables alone incompletely predict biochemical recurrence, and the tissue genomic assays in use are proprietary and priced per patient. This study evaluated whether a transcriptomic panel locked in advance, ProstEx, adds discrimination for biochemical recurrence over the clinical model, and whether it ranks future metastasis from the diagnostic biopsy. METHODS Five public prostatectomy cohorts and a Belfast radiotherapy cohort were analyzed under specifications frozen before outcomes were examined. No patient was scored by a model fitted on his own cohort. The primary outcome was biochemical recurrence. Discrimination was measured with the C statistic of Harrell with patient level bootstrap intervals. Added value was measured as the paired change in C, net benefit and reclassification. RESULTS In the primary set (288 men, 107 events), evaluated by leave one cohort out validation so that every read is external, the panel raised C from 0.683 to 0.724 (paired change + 0.041, 95% CI 0.011 to 0.070). In the secondary set (795 men, 181 events) the change was + 0.053 (0.033 to 0.074). On the same patients, the leading panel score stood level with the cell cycle progression score, and the panel added net benefit at decision thresholds of 0.40 and 0.50. The panel also ranked future metastasis from the diagnostic biopsy (C 0.511 to 0.631, change + 0.120, internal resampling), and its locked metastasis score read an AUC of 0.627 on 212 external events. On the distinct disease free survival endpoint the panel did not add (change − 0.039, − 0.071 to − 0.011). CONCLUSIONS A locked and open transcriptomic panel adds discrimination and net benefit for biochemical recurrence over the clinical model across independent cohorts, with a supporting read for metastasis at the diagnostic biopsy. Prospective validation in a contemporary cohort is the next step.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-20
DOI
https://doi.org/10.21203/rs.3.rs-11789221/v1
Primary Topic
Prostate Cancer Diagnosis and Treatment
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

A locked transcriptomic panel improves prediction of biochemical recurrence after radical prostatectomy

Vinoth Sittaramane
Research Square
Prostate Cancer Diagnosis and Treatment
preprint

A locked transcriptomic panel improves prediction of biochemical recurrence after radical prostatectomy

Vinoth Sittaramane
preprint en

Abstract

BACKGROUND After radical prostatectomy, clinical variables alone incompletely predict biochemical recurrence, and the tissue genomic assays in use are proprietary and priced per patient. This study evaluated whether a transcriptomic panel locked in advance, ProstEx, adds discrimination for biochemical recurrence over the clinical model, and whether it ranks future metastasis from the diagnostic biopsy. METHODS Five public prostatectomy cohorts and a Belfast radiotherapy cohort were analyzed under specifications frozen before outcomes were examined. No patient was scored by a model fitted on his own cohort. The primary outcome was biochemical recurrence. Discrimination was measured with the C statistic of Harrell with patient level bootstrap intervals. Added value was measured as the paired change in C, net benefit and reclassification. RESULTS In the primary set (288 men, 107 events), evaluated by leave one cohort out validation so that every read is external, the panel raised C from 0.683 to 0.724 (paired change + 0.041, 95% CI 0.011 to 0.070). In the secondary set (795 men, 181 events) the change was + 0.053 (0.033 to 0.074). On the same patients, the leading panel score stood level with the cell cycle progression score, and the panel added net benefit at decision thresholds of 0.40 and 0.50. The panel also ranked future metastasis from the diagnostic biopsy (C 0.511 to 0.631, change + 0.120, internal resampling), and its locked metastasis score read an AUC of 0.627 on 212 external events. On the distinct disease free survival endpoint the panel did not add (change − 0.039, − 0.071 to − 0.011). CONCLUSIONS A locked and open transcriptomic panel adds discrimination and net benefit for biochemical recurrence over the clinical model across independent cohorts, with a supporting read for metastasis at the diagnostic biopsy. Prospective validation in a contemporary cohort is the next step.

Research Square
Sam Houston State University (US)
U.S. Department of Education, American Association of Colleges of Osteopathic Medicine
Good health and well-being
Prostate Cancer Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon